ArticleTheranostics2023
Engineering CAR-T cells for radiohapten capture in imaging and radioimmunotherapy applications.
Open access · goldAbstract read
In one paragraph
Article in Theranostics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 16 citations in OpenAlex.
- Whole-body CD8Nature communications · 2025Trial
- Challenges in tracer development for tumor microenvironment (TME) imaging.European journal of nuclear medicine and molecular imaging · 2026Review
- Establishment ofMolecular pharmaceutics · 2026Article
- Targeted cellular micropharmacies deliver therapeutic agents to the brain.EMBO molecular medicine · 2026Article
- Immunotheranostics in Solid Tumors: Longitudinal Tracking of Human IL13Rα2 CAR-T Cells In Vivo.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Chimeric antigen receptor technology: an emerging translational immunotherapy in nonneoplastic diseases.Frontiers in immunology · 2026Review
- Ultrasensitive In Vivo Imaging of Adoptive Immune Cell Distribution and Expansion Using Second Near-Infrared Conjugated Oligoelectrolyte Probes.Research (Washington, D.C.) · 2026Article
- A bibliometric analysis of challenges and advancements in the integrated application of nanoparticles and chimeric antigen receptor T cell therapy.Human vaccines & immunotherapeutics · 2025Article
- Development of a DNA Aptamer-Based Approach to Noninvasively Image CAR-T Cells In Vivo and Traceless Enrichment In Vitro.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Radionuclide-Labeled Biomaterials: A Novel Strategy for Tumor-Targeted Therapy.Biomimetics (Basel, Switzerland) · 2025Review
- Recent developments in translational imaging of in vivo gene therapy outcomes.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
- Proceedings of the National Cancer Institute Workshop on combining immunotherapy with radiotherapy: challenges and opportunities for clinical translation.The Lancet. Oncology · 2025Article
- Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition.Journal of hematology & oncology · 2025Review
- Gas Vesicle-Assisted Ultrasound Imaging for Effective Anti-Tumour CAR-T Cell Immunotherapy Efficacy in Mice Model.International journal of nanomedicine · 2025Article
- Development of an antigen-based approach to noninvasively image CAR T cells in real time and as a predictive tool.Science advances · 2024Article
- Harnessing the power of f-block elements in radiopharmaceuticals.Nature reviews. Chemistry · 2024Article
- Alpha-Emitting Radionuclides: Current Status and Future Perspectives.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Low-dose targeted radionuclide therapy synergizes with CAR T cells and enhances tumor response.Frontiers in immunology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 2 institutions in 1 country.
Keifer KurtzMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Laura EiblerMolecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Megan M DacekMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Lukas M CarterDepartment of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Darren R VeachRadiochemistry and Imaging Sciences Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Samantha LovibondMolecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Emma ReynaudMolecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Sarah QureshyMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Michael R McDevittRadiochemistry and Imaging Sciences Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Christopher BourneMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Sebastien MonetteLaboratory of Comparative Pathology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, and The Rockefeller University, New York, NY 10065, USA.
Blesida PunzalanMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Shireen KhayatMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Svena VermaDepartment of Pharmacology, Weill Cornell Medical College, New York, NY 10065, USA.
Adam L KesnerDepartment of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Nai-Kong V CheungDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Heiko SchöderMolecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Leah GajeckiMolecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Sarah M ChealMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Steven M LarsonMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
David A ScheinbergMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Simone KrebsMolecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Memorial Sloan Kettering Cancer Center · USCornell University · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MClinical and Translational Science AwardUL1TR001873 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI REILLY, MUREDACH P · 2016 to 2025
$99.0MDisparities in COVID Disease Severity and Outcomes in New York CityUL1TR002384 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI JULIANNE L IMPERATO-MCGINLEY · 2017 to 2026
$86.2MT LYMPHOCYTE SUBSET FUNCTION POST-TRANSPLANTATIONP01CA023766 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI O'REILLY, RICHARD JOHN · 1985 to 2023
$59.0MTranslating Stress Response Targeted Therapy for B-Cell LymphomasP50CA192937 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI DALLA-FAVERA, RICCARDO, ZELENETZ, ANDREW D. · 2016 to 2020
$10.9MUnderstanding and Mimicking TCR Recognition with Therapeutic Monoclonal Antibodies.R35CA241894 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI DAVID A SCHEINBERG · 2020 to 2026
$7.2MRECOMBINANT ANTICD33 ANTIBODY FOR AMLR01CA055349 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SCHEINBERG, DAVID A · 1991 to 2020
$6.8MDOTA-based pre-targeting of alpha emittersR01CA233896 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI CHEAL, SARAH MARIE · 2019 to 2023
$3.4MInterrogating the in vivo pharmacokinetics of armored CARs with radiohapten captureR37CA262557 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Simone Krebs · 2021 to 2026
$3.4MPredoctoral Training in Pharmacological SciencesT32GM141949 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI Kristen Elizabeth Pleil · 2021 to 2026
$2.5MDevelopment of a Novel Peptide Platform for Targeted PET Imaging and Radiotherapy of Breast CancerF32EB025050 · NIBIB · SLOAN-KETTERING INST CAN RESEARCH · PI CARTER, LUKAS MICHAEL · 2017 to 2019
$179kEngineering CAR T cells to potentiate innate and adaptive immunityF31CA239511 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI DACEK, MEGAN · 2019 to 2021
$114kNCATS NIH HHS UL1 TR001873NCATS NIH HHS UL1 TR002384NCI NIH HHS F31 CA239511NCI NIH HHS P01 CA023766NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA192937NCI NIH HHS R01 CA055349NCI NIH HHS R01 CA233896NCI NIH HHS R35 CA241894NCI NIH HHS R37 CA262557NIBIB NIH HHS F32 EB025050NIGMS NIH HHS T32 GM141949
Abstract
PubMed holds no abstract for this paper.
Indexed as
Antineoplastic AgentsRadioimmunotherapyImmunotherapy, AdoptivePositron Emission Tomography Computed TomographyRadioisotopesTissue DistributionT-LymphocytesAntineoplastic AgentsRadioisotopesalpha-particlesCAR-T cellsreporter geneT cell trackingtheranostic
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.